CSP
3 min read
52

Navamedic launches Eroxon[®] in Finland

November 6, 2024
0

Reading Time: 2 minutes Oslo, 6 November 2024 – Building on the successful product launch of Eroxon® in Norway and Sweden earlier this year, Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, is now launching Eroxon®

Continue Reading
Technology Holdings Has Expanded Operations into Brazil, Driving Growth in Latin America
BWI
2 min read
34

Technology Holdings Has Expanded Operations into Brazil, Driving Growth in Latin America

November 6, 2024
0

Reading Time: 2 minutes Sao Paulo, Brazil:   Technology Holdings (TH), an award-winning global boutique investment bank with a track record of closing transactions in 24 countries, proudly announces its strategic expansion into Brazil, leveraging digital transformation within one of Latin America’s largest economies.  

Continue Reading
CSP
4 min read
9

Kesko updates its sustainability strategy

November 6, 2024
0

Reading Time: 3 minutes Kesko has updated its sustainability strategy, setting emission reduction targets for its own operations extending to 2034. Over the next 10 years, Kesko will be increasing its investments in energy efficiency and the electrification of transports in an effort to reduce emissions.

Continue Reading
BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 2024
BWI
14 min read
34

BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 2024

November 6, 2024
0

Reading Time: 11 minutes San Mateo, Calif., United States:   Five-year results of Phase 3 SEQUOIA study demonstrate durable benefits of BRUKINSA in patients with CLL Two oral presentations showcase promising safety and efficacy data for BTK chimeric degradation activation compound (CDAC), BGB-16673 Oral presentation highlights

Continue Reading
CSP
10 min read
9

DUG Foodtech announces the outcome of the rights issue

November 6, 2024
0

Reading Time: 7 minutes NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR IN ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR

Continue Reading
Diageo India Releases 2024 ESG Reporting Index Highlights Achievements Across Its ‘Spirit of Progress’ Goals
BWI
9 min read
31

Diageo India Releases 2024 ESG Reporting Index Highlights Achievements Across Its ‘Spirit of Progress’ Goals

November 6, 2024
0

Reading Time: 6 minutes ​ Diageo India (United Spirits Ltd.), among the country’s leading alco-bev companies, launched its third annual ESG Reporting Index 2024 today, highlighting continued progress in the company’s ‘Spirit of Progress’ ESG action plan. The Reporting Index shares impacts across three key objectives outlined in Diageo’s Spirit

Continue Reading
Burjeel Holdings and Response Plus Medical launch mn Human Energy Health and Wellbeing Award
BWI
3 min read
36

Burjeel Holdings and Response Plus Medical launch $1mn Human Energy Health and Wellbeing Award

November 6, 2024
0

Reading Time: 3 minutes Abu Dhabi, United Arab Emirates:   Burjeel Holdings, a leading super-specialty healthcare provider in the MENA region, and Response Plus Medical Services (RPM), the largest pre-hospital care and emergency medical services provider in the region, have jointly launched the $1 million Human

Continue Reading
CSP
1 min read
15

#24-380 Delisting of Derivatives from NGM

November 6, 2024
0

Reading Time: < 1 minute Information about certain derivatives that will be delisted from NGM. For further information concerning this NGM notice please contact NGM Listing department on listings@ngm.se. Nordic Growth Market NGM AB About NGM Nordic Growth Market NGM AB (NGM) is an authorized

Continue Reading
CSP
3 min read
20

BLA for pegzilarginase in the treatment of arginase 1 deficiency (ARG1-D) accepted for priority review by the U.S. FDA

November 6, 2024
0

Reading Time: 2 minutes Stockholm, November 5, 2024: Immedica announces today that the Biologics License Application (BLA) for pegzilarginase in the treatment of arginase 1 deficiency (ARG1-D) has been successfully validated and accepted for priority review by the U.S. Food and Drug Administration (FDA). Anders

Continue Reading
CSP
5 min read
16

Diamyd Medical and INNODIA partner for Type 1 Diabetes awareness and patient recruitment for the DIAGNODE-3 precision medicine trial

November 6, 2024
0

Reading Time: 3 minutes Diamyd Medical has entered a strategic partnership with INNODIA, an international non-profit organization dedicated to advancing research on disease modifying therapies for Type 1 Diabetes. The partnership will leverage INNODIA’s extensive EU-based clinical network with the aim to further amplify patient enrolment

Continue Reading